NYX-2925   Click here for help

GtoPdb Ligand ID: 11289

Synonyms: NYX2925
Compound class: Synthetic organic
Comment: NYX-2925 is a oral, brain-penetrating, NMDA receptor modulator that was developed by Aptinyx [2]. It acts as a co-agonist to glutamate and partially activates NMDARs. NYX-2925 is being investigated for potential to modulate neural pathways relevant for chronic pain.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 103.94
Molecular weight 297.17
XLogP -1.69
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CC(C(=O)N1CCC[C@@]21CN(C2=O)[C@H](C(=O)N)[C@H](O)C)C
Isomeric SMILES CC(C(=O)N1CCC[C@@]21CN(C2=O)[C@H](C(=O)N)[C@H](O)C)C
InChI InChI=1S/C14H23N3O4/c1-8(2)12(20)17-6-4-5-14(17)7-16(13(14)21)10(9(3)18)11(15)19/h8-10,18H,4-7H2,1-3H3,(H2,15,19)/t9-,10+,14-/m1/s1
InChI Key NFXPEHLDVKVVKA-ISTVAULSSA-N
No information available.
Summary of Clinical Use Click here for help
NYX-2925 is being evaluated in clinical trials for potential to treat chronic pain conditions, such as diabetic peripheral neuropathy and fibromyalgia.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03249103 Evaluate the Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia Phase 2 Interventional Aptinyx
NCT04147858 Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia Phase 2 Interventional Aptinyx
NCT02834741 Safety, Tolerability, PK of Oral NYX-2925 in Healthy Volunteers Phase 1 Interventional Aptinyx First-in-human trial results indicated that NYX-2925 was safe and well-tolerated in healthy volunteers and confirmed that the compound crosses the blood brain barrier. 1
NCT04146896 Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy (DPN) Phase 2 Interventional Aptinyx A company announcement in April 2022 stated that by 12 weeks, NYX-2925 failed to improve pain scores compared to placebo in patients with painful diabetic peripheral neuropathy.